Price reduction is commitment by Bharat Biotech, made possible through partnership with GSK and driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins

降价是巴拉特生物技术公司的承诺，通过与GSK的合作成为可能，并通过工艺改进、扩大生产能力、具有成本效益的制造和最低利润空间来推动实现。

Bharat Biotech and GSK make this announcement as part of their pledges to Gavi replenishment process for 2026 - 2030

Bharat Biotech 和 GSK 在其对 2026 - 2030 年 Gavi 补充进程的承诺中做出了这一宣布。

Through Gavi support, RTS,S expected to be rolled out in 12 endemic countries in Africa through routine immunisation programmes by end of 2025

通过全球疫苗免疫联盟的支持，预计到2025年底，RTS,S疫苗将通过常规免疫计划在非洲的12个流行国家推广。

Bharat Biotech International Limited (BBIL) and GSK plc (LSE/NYSE: GSK) today announce their commitment to Gavi, the Vaccine Alliance (Gavi), in the continued roll out of the world’s first malaria vaccine, RTS,S. Bharat Biotech will be reducing the price of RTS,S, developed by GSK, PATH and partners, by more than half, to less than $5 progressively by 2028.

印度巴拉特生物技术国际有限公司（BBIL）和葛兰素史克（GSK）今天宣布，他们将继续致力于支持全球疫苗免疫联盟（Gavi），推进全球首款疟疾疫苗RTS,S的推广。到2028年，巴拉特生物技术公司将把由GSK、PATH及其合作伙伴研发的RTS,S疫苗价格降低一半以上，逐步降至不到5美元。

This price reduction is driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins. The announcement forms part of pledges to Gavi for its next replenishment phase (Gavi 6.0, 2026-2030) by both companies..

这一价格下调的驱动因素包括工艺改进、产能扩大、成本效益制造以及最低的利润边际。该公告是两家公司对Gavi下一阶段增资（Gavi 6.0，2026-2030）承诺的一部分。

RTS,S was the first malaria vaccine recommended by the World Health Organization (WHO) in 2021. Since then, GSK has made significant investments to enhance production capacity and efficiency, and to undertake the planned technology transfer to Bharat Biotech. In parallel, Bharat Biotech has invested over $200 million in new, higher-output manufacturing facilities, product development and technology transfers.

RTS,S 是世界卫生组织 (WHO) 于 2021 年推荐的第一种疟疾疫苗。自那时起，GSK 进行了大量投资以提高生产能力与效率，并推进计划中的技术转让给巴拉特生物技术公司 (Bharat Biotech)。同时，巴拉特生物技术公司已投资超过 2 亿美元用于建设新的高产量生产设施、产品研发和技术转让。

These enhancements have enabled a phased reduction in the price of the malaria vaccine, starting immediately and fully realised by 2028, when the transfer of production between the two companies is complete..

这些改进使疟疾疫苗的价格得以逐步降低，降价从现在开始，并在两家公司完成生产转移的2028年全面落实。

With Gavi’s support, 12 endemic countries in Africa will have introduced RTS,S through routine immunisation programmes by the end of 2025. This has only been possible through the critical work that GSK has undertaken with Bharat Biotech, PATH, together with the WHO, implementing countries, MedAccess and Gavi, to help deliver access to life-saving malaria prevention for children in endemic countries in Africa..

在Gavi的支持下，到2025年底，非洲的12个流行国家将通过常规免疫计划引入RTS,S疫苗。这只有通过GSK与巴拉特生物技术公司、PATH、世界卫生组织、实施国家、MedAccess和Gavi共同开展的关键工作才成为可能，这些努力帮助为非洲流行国家的儿童提供了获得挽救生命的疟疾预防的机会。

Dr. Krishna Ella, Executive Chairman of Bharat Biotech International Limited said:

巴拉特生物技术国际有限公司执行董事长克里希纳·埃拉博士说：

'This pledge to Gavi 6.0 is more than a pricing announcement. It's a commitment to global equity, innovation, and collaboration. Through this historic announcement, we aim to change the course of malaria burden for millions of children and families. For us, this is more than a cooperation, it’s a promise.

“对Gavi 6.0的这一承诺不仅仅是一个定价公告，更是对全球公平、创新与合作的承诺。通过这一历史性公告，我们旨在改变数百万儿童和家庭的疟疾负担。对我们而言，这不仅是一次合作，更是一个承诺。

By joining forces with GSK, and working closely with Gavi, and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria. At Bharat Biotech, we believe technology must deliver on three essentials: safety, affordability, and accessibility.

通过与GSK合作，并与Gavi和世界卫生组织密切合作，我们正在切实迈向缩小疫苗供应与面临疟疾风险的儿童的迫切需求之间的差距。在巴拉特生物技术公司，我们相信技术必须满足三个基本要素：安全性、可负担性和可及性。

With this collaboration, we are turning this belief into real impact, with the aim of ensuring life-saving vaccines reach the communities that need them most.”.

通过此次合作，我们将把这一信念转化为实际影响，旨在确保拯救生命的疫苗能够到达最需要它们的社区。

Thomas Breuer, Chief Global Health Officer, GSK, said:

葛兰素史克（GSK）首席全球卫生官托马斯·布罗尔表示：

'We partnered with Bharat Biotech in 2021 with a common goal: to find a sustainable solution to get ahead of malaria. Today, we announce GSK’s contribution to the long-term price ambition of the world's first malaria vaccine, a key milestone achieved through collaboration with Bharat Biotech and partners from Gavi, PATH and the WHO.

“我们于2021年与巴拉特生物技术公司合作，共同目标是寻找一种可持续的解决方案以遏制疟疾。今天，我们宣布GSK为世界上首款疟疾疫苗的长期价格目标做出贡献，这是通过与巴拉特生物技术公司以及来自Gavi、PATH和世卫组织的合作伙伴协作取得的关键里程碑。

This demonstrates our commitment to changing the trajectory of infectious diseases like malaria, making a difference in the lives of children and families across Africa. The GSK team has worked hand in hand with Bharat Biotech to transfer the vaccine manufacturing technology, while simultaneously implementing crucial improvements in manufacturing efficiencies, resulting in today’s pledge to the Gavi replenishment.”.

这表明了我们致力于改变疟疾等传染病的发展轨迹，为非洲各地的儿童和家庭的生活带来改变。GSK团队与巴拉特生物技术公司携手合作，转让疫苗生产技术，同时实施生产效率的关键改进，从而促成了今天对Gavi补充资金的承诺。"

The body of data generated from studies of the malaria vaccine developed by GSK, PATH and partners spans multiple years in malaria endemic countries, multiple seasons and in high transmission settings. In a recent evaluation of impact by the WHO of the Malaria Vaccine Implementation Programme (MVIP) in Ghana, Kenya and Malawi, where over 2 million children received the RTS,S vaccine between 2019 and 2023, the WHO reported a 13% reduction in all-cause mortality and a 22% reduction in hospitalisations of severe malaria among children age-eligible for vaccination during this period.

由GSK、PATH及其合作伙伴开发的疟疾疫苗研究生成的数据跨越多个年份、多个季节，并涵盖高传播地区的疟疾流行国家。在世界卫生组织（WHO）最近对加纳、肯尼亚和马拉维的疟疾疫苗实施计划（MVIP）影响评估中，2019年至2023年期间有超过200万名儿童接种了RTS,S疫苗。WHO报告称，在此期间，符合接种年龄的儿童全因死亡率下降了13%，重症疟疾住院率降低了22%。

1

1

. When administered seasonally in regions with high malaria transmission, alongside seasonal malaria chemoprevention, the two malaria vaccines recommended by the WHO, have been shown to prevent approximately 75% of malaria episodes

在疟疾传播率高的地区，结合季节性疟疾化学预防措施，世卫组织推荐的两种疟疾疫苗在季节性接种时已被证明可预防大约 75% 的疟疾病例。

2

2

.

。

Malaria vaccines are part of the malaria “tool box” alongside other interventions such as seasonal chemoprevention, malaria treatments, Indoor Residual Spraying (IRS) and bed nets. While no single intervention recommended by the WHO for malaria control is sufficiently efficacious to serve as a standalone intervention, malaria vaccines are one of the high-impact malaria interventions.

疟疾疫苗是疟疾“工具箱”的一部分，与其他干预措施并用，例如季节性化学预防、疟疾治疗、室内残留喷洒（IRS）和蚊帐。尽管世界卫生组织推荐的任何单一疟疾控制干预措施都不足以单独发挥作用，但疟疾疫苗是高影响力的疟疾干预措施之一。

Building on this foundation, research has begun at GSK to develop a new vaccine designed to further improve protection for children in endemic countries against the most severe form of malaria. By targeting a different stage of the life-cycle of the malaria parasite, this work aims to evolve and expand the global malaria “tool box,” in support of elimination efforts..

基于这一基础，GSK已经开始研究开发一种新疫苗，旨在为流行国家的儿童提供针对最严重疟疾形式的进一步保护。通过靶向疟原虫生命周期的不同阶段，这项工作旨在发展和扩充全球疟疾“工具箱”，以支持消除疟疾的努力。

Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance said:

Gavi疫苗联盟的首席执行官萨尼亚·尼什塔尔博士说：

“We are grateful to GSK and Bharat Biotech for their innovation and commitment to protecting millions of children and communities from malaria. With the support of our partners, Gavi has helped 20 countries in Africa – nations that together shoulder over 70% of the global malaria burden – protect their children, communities and health systems.

“我们感谢GSK和巴拉特生物技术公司的创新和致力于保护数百万儿童和社区免受疟疾的侵害。在我们的合作伙伴的支持下，Gavi已经帮助了非洲的20个国家——这些国家共同承担了全球70%以上的疟疾负担——保护他们的儿童、社区和卫生系统。

Our ambition is to protect at least 50 million more children across Africa by the end of 2030, and this collaboration between GSK and Bharat Biotech helps put this goal firmly within reach.”.

我们的目标是到2030年底再保护非洲至少5000万儿童，而GSK与巴拉特生物技术公司的合作有助于将这一目标牢牢地置于可实现的范围内。

Dr Kwaku Poku Asante, Director of the Kintampo Health Research Centre, said:

库瓦库·波库·阿桑特博士，金坦博健康研究中心主任，说道：

“As an epidemiologist working in malaria vaccine development and delivery, I have seen the impact malaria vaccines are already having on children in high-burden regions of Africa. As a result of the collaboration between the research community in implementing endemic countries, industry, NGOs and multilateral organisations, the world’s first malaria vaccine is helping to reduce all-cause mortality and hospitalisations of severe malaria among children.

“作为一名从事疟疾疫苗开发与推广的流行病学家，我亲眼目睹了疟疾疫苗在非洲高负担地区对儿童已经产生的影响。通过在实施流行国家的研究界、产业界、非政府组织和多边机构之间的合作，世界上首个疟疾疫苗正在帮助减少儿童因疟疾导致的全因死亡率和重症住院情况。

Today’s announcement of a long-term price reduction by Bharat Biotech, with GSK’s contribution, marks a pivotal moment for the malaria community. Any lower cost vaccine means children in the most affected communities in endemic countries can be protected. Sustained affordability is essential to ensuring that the progress we’ve made in malaria control is not only maintained, but accelerated.”.

今天，巴拉特生物技术公司宣布长期降价，加之GSK的贡献，这标志着疟疾防治领域的一个关键时刻。任何更低价格的疫苗都意味着在流行国家中受影响最严重的社区的儿童可以得到保护。持续的可负担性对于确保我们在疟疾控制方面取得的进展不仅得以维持，而且加速推进至关重要。

About Bharat Biotech International Limited (BBIL)

关于巴拉特生物技术国际有限公司 (BBIL)

BBIL is a biotechnology company headquartered in Genome Valley, Hyderabad, India, focused on providing affordable vaccines and bio-therapeutics for combating infectious diseases. BBIL has more than 145 global patents, a product portfolio of more than 19 vaccines and four biotherapeutics, registrations in more than 125 countries, and the World Health Organization (WHO) Pre-qualifications.

BBIL是一家总部位于印度海得拉巴基因组谷的生物技术公司，专注于提供可负担的疫苗和生物治疗药物以对抗传染病。BBIL拥有超过145项全球专利，超过19种疫苗和四种生物治疗药物的产品组合，在125多个国家注册，并获得世界卫生组织（WHO）预认证。

BBIL has delivered more than 9 billion doses of vaccines worldwide, and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis, Rabies, Cholera Chikungunya, Zika, and the world’s first tetanus-toxoid conjugated vaccine for Typhoid. To address the COVID-19 pandemic, the company developed its indigenous COVID-19 vaccines..

BBIL已在全球范围内交付了超过90亿剂疫苗，并开发了针对甲型H1N1流感、轮状病毒、乙型脑炎、狂犬病、霍乱、基孔肯雅热、寨卡病毒的疫苗，以及全球首款针对伤寒的破伤风类毒素结合疫苗。为应对新冠疫情，该公司还研发了其本土的新冠疫苗。

To learn more about Bharat Biotech, visit

要了解更多信息关于巴拉特生物技术公司，请访问

www.bharatbiotech.com

www.bharatbiotech.com

.

。

About GSK

关于GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

GSK是一家全球生物制药公司，致力于联合科学、技术和人才，共同战胜疾病。欲了解更多信息，请访问gsk.com。

Cautionary statement regarding forward-looking statements

关于前瞻性声明的谨慎声明

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2024, and GSK’s Q1 Results for 2025..

GSK提醒投资者，GSK所做的任何前瞻性声明或预测，包括本公告中所包含的内容，均受可能导致实际结果与预测结果存在重大差异的风险和不确定性的影响。这些因素包括但不限于GSK 2024年Form 20-F年度报告中“风险因素”部分以及GSK 2025年第一季度业绩报告中描述的内容。

References

参考文献

World Health Organization, World Malaria Report 2024

世界卫生组织，《2024年世界疟疾报告》

https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024

https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024

(Accessed June 2025)

（引用日期：2025年6月）

World Health Organization,

世界卫生组织，

Malaria vaccines (RTS,S and R21)

疟疾疫苗（RTS,S 和 R21）

(Accessed June 2025)

（访问于2025年6月）